Pharmaceuticals and life sciences
High-value inventory and regulatory oversight demand strict governance.
Pharmaceutical challenge
High unit values, API (active pharmaceutical ingredients) €10K–€100K+ per kg; finished products €100–€10K+ per unit; biologics and specialty €50K–€500K+ per treatment; clinical trial inventory: high cost, uncertain approval.
Major pharmaceutical companies typically carry inventory valued at hundreds of millions to over a billion dollars, caused by long production cycles. API synthesis typically requires 3–12 months; formulation and scale-up manufacturing add another 2–6 months; and quality testing plus batch release take 1–3 months, with regulatory reviews or holds adding variable additional delays. Overall, total cycle time from raw-material procurement to fully approved finished goods generally spans 6–24 months.
The financial impact
Pharmaceutical working capital is dominated by inventory.
40–60% of working capital is typically inventory.
Pharmaceutical inventory faces
a specific form of obsolescence: expiration.
Recoverable exposure
Demand fluctuations that require careful inventory repositioning, persistent pricing pressure in highly competitive markets, and strategic product‑mix adjustments aimed at better aligning supply with rapidly shifting customer demand.
Permanent loss
Product expiration (zero salvage value post-expiry), regulatory holds preventing sale, product discontinuation or recall, generic entry forcing write-offs. Expiration is permanent, time-certain obsolescence. Unlike price erosion, expired inventory has zero value. Large pharmaceutical companies commonly experience tens to hundreds of millions in annual write-offs for expiration and obsolescence.
Strict regulatory requirements, including compliance with FDA, EMA, and relevant local health authority rules; adherence to Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards; robust serialization and traceability measures to meet DSCSA and FMD obligations; stringent cold chain management and controlled‑substance handling protocols; and ongoing audit and inspection readiness.
Typical shelf life ranges from 12 to 36 months. Because expired products have no salvage value, expiration write-offs represent a complete loss to the organization. These items demand careful stock rotation and strict FEFO management due to the added handling, monitoring, and tracking complexity.
How Procura supports pharmaceuticals
Regulatory-grade documentation
FDA/EMA-compliant chain of custody, serialization and traceability (lot/batch level) with full documentation, GDP-compliant handling, continuous temperature monitoring and complete cold chain records, and ongoing audit and inspection readiness.
Result: Compliance confidence with financial clarity.
High-value inventory capital
Recognition of regulatory hold risk, accommodation of extended production cycles, flexibility to support clinical trial and launch inventory buildups, and seamless integration with revenue recognition.
Result: liquidity for R&D; and operations without inventory-driven capital constraints.
Expiration and obsolescence management
Real-time expiration tracking by SKU and location, FEFO rotation optimisation and automated alerts, financial impact forecasting with scenario modelling, disposition planning (donation, destruction, write-off) and streamlined execution workflows, product discontinuation and obsolescence management, plus planning for the impact of generic entry and supply changes.
Result: proactive management of pharmaceutical-specific risks.
Take the next step
Discover how Procura helps organisations manage inventory as an enterprise capability
Discuss your inventory challenges with us
Discover Procura's proprietary inventory platform
Please see our Privacy & Cookie Policy regarding how we will handle this information.